SBFM

A pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to provide an update on the progress of the IND-Enabling studies of Adva-27a, the Company's flagship oncology drug candidate. To date, the Company has completed seven in vitro studies in which Adva-27a has shown potent anti-tumor activity in every cell line tested, including multidrug resistant breast cancer, multidrug resistant uterine cancer and small-cell lung cancer, for which today's approved therapies have little or no efficacy.